PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
NEW YORK, Jan. 11, 2022 /PRNewswire/ -- PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the...